Anuoluwapo Bode-Oloye
NURS 6630 Psychopharmacology
Attention Deficit Hyperactivity Disorder
04/29/2018
, ADHD| Anu Bode-Oloye
Attention Deficit Hyperactivity Disorder (ADHD)
ADHD is a childhood-onset disorder categorized as developmentally inappropriate levels
of inattention. The economic impact of ADHD on the U.S. economy has been substantial,
resulting in nearly $138 billion in lost income and productivity among children and adolescents
per year (Li, J.J., & Lansford, 2018). ADHD is a common presenting behavioral problem in
pediatric primary care with the prevalence estimate reported at 7.2% (Moore et al. 2018). Social
difficulties are the central area of functional impairment for most children with ADHD. The
problem encountered by these children range from complications in making and maintaining
friendships, peer rejection and neglect and increased negative peer and caregiver interactions
(Kofler et al. 2018). Impaired social functioning is viewed as one of the core deficits for children
with ADHD. The children with ADHD present with deficiencies in the following domains
which includes problem-solving, planning, plasticity, orienting, response inhibition, continued
attention and working memory (Cordier et al. 2018).
Decision # 1
Begin Ritalin (methylphenidate) chewable tablets 10 mg orally in the morning
Methylphenidate (MPH: Ritalin) is a drug used for the treatment of attention deficit
hyperactivity disorder (ADHD) and is frequently used as a cognitive enhancer. The MPH
treatment is initiated with immediate release formulations to titrate the dose depending on the
individual effect, duration, and severity of symptoms (Haertling, Mueller & Blike-Hentsch
2015). MPH increases the dopamine release by blocking the DA transporter in the human
striatum (Tohru et al. 2017). MPH is used to enhance cognitive and attention task performance in
human. In the study of human imaging, studies of MPH show improved efficiency of the
2
NURS 6630 Psychopharmacology
Attention Deficit Hyperactivity Disorder
04/29/2018
, ADHD| Anu Bode-Oloye
Attention Deficit Hyperactivity Disorder (ADHD)
ADHD is a childhood-onset disorder categorized as developmentally inappropriate levels
of inattention. The economic impact of ADHD on the U.S. economy has been substantial,
resulting in nearly $138 billion in lost income and productivity among children and adolescents
per year (Li, J.J., & Lansford, 2018). ADHD is a common presenting behavioral problem in
pediatric primary care with the prevalence estimate reported at 7.2% (Moore et al. 2018). Social
difficulties are the central area of functional impairment for most children with ADHD. The
problem encountered by these children range from complications in making and maintaining
friendships, peer rejection and neglect and increased negative peer and caregiver interactions
(Kofler et al. 2018). Impaired social functioning is viewed as one of the core deficits for children
with ADHD. The children with ADHD present with deficiencies in the following domains
which includes problem-solving, planning, plasticity, orienting, response inhibition, continued
attention and working memory (Cordier et al. 2018).
Decision # 1
Begin Ritalin (methylphenidate) chewable tablets 10 mg orally in the morning
Methylphenidate (MPH: Ritalin) is a drug used for the treatment of attention deficit
hyperactivity disorder (ADHD) and is frequently used as a cognitive enhancer. The MPH
treatment is initiated with immediate release formulations to titrate the dose depending on the
individual effect, duration, and severity of symptoms (Haertling, Mueller & Blike-Hentsch
2015). MPH increases the dopamine release by blocking the DA transporter in the human
striatum (Tohru et al. 2017). MPH is used to enhance cognitive and attention task performance in
human. In the study of human imaging, studies of MPH show improved efficiency of the
2
